RRM1 and neoplasm: Among the 40 patients treated with gemcitabine, the recurrence rate of tumours with RRM1 overexpression was 66.7%, whereas the recurrence rate of tumours with low RRM1 expression was 27.3% (p ≤ 0.05, Figure 1F).